Featuring an interview with Dr John Allan, including the following topics:
• Update on key studies of acalabrutinib in the front-line setting (0:00)
• Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11)
• Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06)
• Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08)
• Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49)
• Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22)
• Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15)
• Emerging data with novel Bcl-2 inhibitors (1:11:26)
• Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37)
CME information and select publications
Research To Practice | Oncology Videos